Balkrishna Industries has entered a multi-part deal with Italy's Pirelli to collaborate in the passenger car radial (PCR) tyre segment. The roadmap includes an interim manufacturing and technical service arrangement, leading to a planned 50:50 joint venture in India by 2030. This partnership marks a strategic expansion for Balkrishna into the passenger car segment while leveraging Pirelli’s global expertise.
Balkrishna Industries Inks Landmark Pact With Pirelli
Balkrishna Industries (BKT) has entered a strategic multi-part agreement with Pirelli Tyre S.p.A. to enter the passenger car radial (PCR) tyre segment.
Reader Takeaway: BKT gains technical expertise and market entry into PCR, while Pirelli secures Indian manufacturing capacity via a future JV.
What just happened
Balkrishna Industries has signed a Framework, Offtake, and Service Agreement with Italy-based Pirelli. The companies plan to establish a 50:50 joint venture in India by December 31, 2030, which will feature equal shareholding and shared manufacturing capacity. Governance will be split equally with a four-member board and a rotating chairperson.
Why this matters
This deal provides BKT a significant entry point into the lucrative passenger car radial tyre market. By utilizing Pirelli's technical support and brand, BKT diversifies its portfolio beyond its core off-highway tyre (OHT) dominance. For Pirelli, the collaboration establishes a firm manufacturing footprint in India, utilizing BKT’s existing facilities in Bhuj, Gujarat.
The roadmap
Until the joint venture is operational, BKT will act as a manufacturer for Pirelli-branded PCR tyres at its Bhuj plant. Simultaneously, the Service Agreement allows BKT to access Pirelli’s international testing facilities and simulation systems to refine BKT-branded products.
Exclusivity and restrictions
Both companies have agreed to a non-compete clause in India regarding joint ventures for car, light truck, motorcycle, or bicycle tyres. While BKT is barred from manufacturing competing PCR tyres for third parties, the company maintains the right to develop and sell its own BKT-branded PCR range.
What to track next
The progress toward the 2030 JV incorporation and the scaling of the offtake manufacturing at the Bhuj facility will be key performance indicators for investors to monitor over the coming quarters.